

## Ironwood Pharma (IRWD)

**\$10.09** (As of 08/07/20)

Price Target (6-12 Months): **\$11.00**

Long Term: 6-12 Months

**Zacks Recommendation:**

**Neutral**

(Since: 01/05/20)

Prior Recommendation: Outperform

Short Term: 1-3 Months

**Zacks Rank:** (1-5)

**3-Hold**

Zacks Style Scores:

VGM:C

Value: C

Growth: B

Momentum: F

### Summary

Ironwood reported encouraging second-quarter results wherein sales and earnings beat estimates. The company's Linzess has been performing encouragingly on the back of strong demand and expansion in new patient population and geographic regions. Ironwood is focused on further label expansions of the drug. Meanwhile, Ironwood's separation into two companies is increasing operational performance and strategic flexibility. The amendment of agreements related to Linzess rights in China and Japan with its partners is likely to boost margins. Shares have underperformed the industry so far this year. However, competition in Linzess' target markets is intensifying. Any Linzess-related pipeline/regulatory setbacks will weigh heavily on the stock as the rest of its pipeline is couple of year away from commercialization.


### Price, Consensus & Surprise



### Data Overview

52 Week High-Low	<b>\$14.10 - \$7.91</b>
20 Day Average Volume (sh)	<b>2,226,184</b>
Market Cap	<b>\$1.6 B</b>
YTD Price Change	<b>-23.4%</b>
Beta	<b>1.37</b>
Dividend / Div Yld	<b>\$0.00 / 0.0%</b>
Industry	<b>Medical - Drugs</b>
Zacks Industry Rank	<b>Top 48% (122 out of 252)</b>

### Sales and EPS Growth Rates (Y/Y %)



Last EPS Surprise	<b>100.0%</b>
Last Sales Surprise	<b>6.9%</b>
EPS F1 Est- 4 week change	<b>-3.7%</b>
Expected Report Date	<b>NA</b>
Earnings ESP	<b>-20.8%</b>
P/E TTM	<b>11.3</b>
P/E F1	<b>24.0</b>
PEG F1	<b>NA</b>
P/S TTM	<b>3.8</b>

### Sales Estimates (millions of \$)

	Q1	Q2	Q3	Q4	Annual*
2021	83 E	93 E	108 E	124 E	394 E
2020	80 A	89 A	94 E	108 E	362 E
2019	69 A	102 A	131 A	126 A	428 A

### EPS Estimates

	Q1	Q2	Q3	Q4	Annual*
2021	\$0.06 E	\$0.13 E	\$0.21 E	\$0.30 E	\$0.55 E
2020	\$0.04 A	\$0.16 A	\$0.13 E	\$0.19 E	\$0.42 E
2019	-\$0.26 A	\$0.08 A	\$0.40 A	\$0.30 A	\$0.38 A

\*Quarterly figures may not add up to annual.

The data in the charts and tables, including the Zacks Consensus EPS and Sales estimates, is as of 08/07/2020. The reports text is as of 08/10/2020.

## Overview

Cambridge, MA-based Ironwood Pharmaceuticals, Inc. is focused on the development and commercialization of treatments primarily addressing gastrointestinal (GI) diseases. Linzess (linaclotide) was launched in December 2012 in collaboration with Allergan (now a subsidiary of AbbVie) for patients suffering from irritable bowel syndrome with constipation (IBS-C; 290 mcg) or chronic idiopathic constipation (CIC; 145 mcg & 72 mcg). Ironwood and AbbVie co-develop and co-commercialize Linzess and equally share Linzess' U.S. collaboration profits or losses as well as all development costs. Linzess is marketed by Allergan for IBS-C in Europe and Canada under the brand name Constella. Ironwood receives royalties on sales of Constella in Europe and Canada from AbbVie.


In Japan, Ironwood has partnered with Astellas Pharma for the development and commercialization of Linzess and with AstraZeneca in China, Hong Kong and Macau. Linzess received approval for IBS-C indication in Japan in December 2016 and for chronic constipation (CC) in August 2018. Meanwhile in January 2019, the drug was approved in China for IBS-C.

Ironwood has also partnered with AbbVie for the development and commercialization of Linzess in all other territories worldwide.

Meanwhile, in a bid to expand its reach among primary care physicians and gastroenterologists and earn additional funds, Ironwood has signed co-promotion deals with Alnylam for Givlaari [acute hepatic porphyria (AHP)] in the United States.

In April 2019, the company completed the spin-off of its soluble guanylate cyclase (sGC) segment into a separate, publicly traded company, Cyclacel Therapeutics.

Ironwood's revenues in 2019 were up 23.6% to \$428.4 million.



---

## Reasons To Buy:

- ▲ **Linness Performance Encouraging:** Following the approval of Linness in 2012, the sales of the drug has grown significantly on back of strong demand.

Ironwood is working on expanding managed care access to Linness and lowering out-of-pocket costs. Moreover, since 2016 CVS/Caremark has granted Linness an exclusive preferred position on its formulary. The company commenced a new direct-to-consumer (DTC) campaign in April 2020. Previous DTC campaigns have supported the drug's growth. Moreover, withdrawal of prescription MiraLAX is also favorably impacting sales.

Linness has blockbuster potential, if approved for additional indications. We are also encouraged by Ironwood's partnership deals with companies like Allergan.

Linness has the potential to be a blockbuster product. By the end of 2020, Ironwood expects annual sales of Linness to cross \$1 billion. The company is also progressing well with development of the drug in Japan and China. Per IQVIA data, Linness is the leading prescribed drug for adult patients in the United States with IBS-C or CIC. Ironwood estimates that its IBS-C/CIC franchise may represent a peak U.S. sales opportunity of over \$2 billion, with additional global potential. Moreover, Linness is well protected by patents and is unlikely to face generic competition before March 2029. Ironwood and Allergan are working to strengthen the patent further.

- ▲ **Pipeline Progress Encouraging:** Ironwood and Allergan are looking to broaden Linness' label to include new indications and patient populations.

In November 2019, the companies submitted a supplemental new drug application seeking label expansion of Linness in additional abdominal symptoms associated with IBS-C, including bloating and discomfort. Linness is also being evaluated as a potential treatment for pediatric patients with IBS-C and functional constipation. Efforts are on to expand in ex-U.S. territories as well.

Meanwhile, to capture the lucrative GI market, Ironwood is developing several candidates. Its most advanced pipeline candidate is IW-3718, which is being evaluated in two identical phase III studies for treating persistent refractory gastroesophageal reflux disease (GERD). Results from the studies are expected in the first half of 2021.

- ▲ **Strong Partnerships:** We are positive on Ironwood's agreement with AbbVie for the development and commercialization of Linness both in the United States and Europe. Given Allergan's expertise and strong presence both in the United States and EU markets, we believe it is a suitable partner for Ironwood. The company is co-promoting Givlaari as a treatment for AHP with Alynham in the United States.

The company also has a deal with Astellas for the development of Linness in Japan. Ironwood has an agreement with AstraZeneca for Linness in China, Hong Kong and Macau. The collaborations have not only reduced the cost of developing the drug, these also act as a source of revenues for Ironwood. Additional partnerships in other territories will be a positive for the company.

- ▲ **Spin-off of Cyclerion Encouraging:** Separation of Ironwood's sGC pipeline into another entity, Cyclerion, is a positive. The transaction improved operating margin in the past couple of quarters, following the separation, by bringing down research and development costs. The company will also be able to put more efforts in building its GI products, especially Linness. Moreover, the spin-off along with some restructuring initiatives is also reducing the workforce, leading to further decrease in operating expenses. The company's operating cash flow turned positive in the third quarter of 2019.

- ▲ **Favorable Debt Profile:** Ironwood has a favorable debt profile. As of Jun 30, 2020, the company's debt to total capital ratio was 1.08, which compared favorably with the previous quarter's ratio of 1.19. The company's ratio has been declining over the past few quarters. The company had debt to total capital ratio of 1.28 at 2019-end. A lower ratio indicates lower financial risk. Moreover, the company's cash and equivalent of \$255 million is sufficient to pay its short-term debt of \$3 million in case of insolvency. The company's times interest earned improved to 4X in second-quarter 2020, compared with 3.5X in the previous quarter. This suggests that the company is capable of meeting its interest obligations from operating earnings.
-

---

## Reasons To Sell:

▼ **Over-Dependence on Linzess:** While we are pleased with the performance of Linzess, we are concerned about the company's dependence on the product for growth. Any negative news related to Linzess would adversely impact the company and its growth prospects. Although the performance of Linzess improved in 2019, customer buying patterns can have unfavorable impact in future years as seen earlier.

Competition in CIC and IBS-C, Linzess' target markets, is intensifying.

Meanwhile in August 2018, Ironwood terminated its licensing agreement with AstraZeneca related to Zurampic and all products containing lesinurad, including Duzallo (fixed-dose combination of lesinurad and allopurinol). The termination was based on unfavorable data from a study exploring a path for value creation of lesinurad-based products. This has impacted the top line unfavorably as expected. Moreover, upon completion of the termination of lesinurad franchise, the company solely depends on Linzess for the majority of its revenues.

▼ **Pipeline Candidates Still a Few Years from Commercialization:** Ironwood's mid/late-stage nature of the pipeline runs its own risk. Although the company has a late-stage candidate in its pipeline, it will be a couple of years before the candidate is close to commercialization. Moreover, we note that clinical development involves a high degree of risk. Gaining approval for pipeline candidates has become more difficult given the tough regulatory environment. Meanwhile, the company discontinued development of a delayed-release formulation of Linzess, MD-7246, following failure in phase II study in May 2020. Any further development and any regulatory setbacks for pipeline candidates would be a major disappointment for the company and have an adverse impact on shares.

▼ **Competitive and Pricing Pressure:** Currently approved products for IBS-C and CIC include Takeda's Amitiza and Motegrity as well as laxatives and over-the-counter fiber supplements. Additional competition has entered the market in the form of Synergy's Trulance (plecanatide), which is marketed for treating CIC as well as IBS-C. In September 2019, Ardelyx received approval for Isbrela from the FDA for the treatment of IBS-C. Moreover, several other GI candidates are in late-stage development for Linzess' targeted indications. We are concerned about stiff competition limiting the sales potential of Linzess. Linzess is also facing pricing pressure in the United States, which is impacting sales.

---

## Last Earnings Report

### Ironwood Q2 Earnings and Revenues Beat Estimates

Ironwood reported second-quarter 2020 adjusted earnings of 16 cents per share, which beat the Zacks Consensus Estimate of 8 cents. The company had reported adjusted earnings of 10 cents per share in the year-ago quarter.

Total revenues of \$89.4 million also beat the Zacks Consensus Estimate of \$83.7 million. However, revenues were down 12.5% year over year due to the absence of linaclotide API sales.

Quarter Ending **06/2020**

Report Date	<b>Aug 06, 2020</b>
Sales Surprise	<b>6.89%</b>
EPS Surprise	<b>100.00%</b>
Quarterly EPS	<b>0.16</b>
Annual EPS (TTM)	<b>0.90</b>

### Quarter in Detail

As reported by partner AbbVie, Linzess net sales totaled \$219 million in the United States, up 5.4% year over year.

Ironwood's share of net profits from the sales of Linzess in the United States (included in collaborative revenues) was \$86.5 million in the second quarter, up approximately 15.3% year over year.

Per data provided by IQVIA, volume of prescribed Linzess capsules in the second quarter increased about 9% year over year.

Revenues also include \$1.8 million in linaclotide royalties, \$0.9 million in co-promotion revenues, and \$0.2 million in other revenues.

On its second-quarter earnings call, Ironwood stated that the COVID-19 pandemic has not caused significant disruptions to manufacturing operations nor supply of Linzess in the United States. The company has enough supply of Linzess to meet U.S. demand in 2020.

### 2020 Guidance

Ironwood re-issued its outlook for 2020 after withdrawing the same on the first-quarter earnings call due to uncertainty related to COVID-19 pandemic.

The company expects net sales of Linzess to grow in mid-single percentage points in 2020. Total revenues are anticipated in the range of \$360 million-\$380 million. The company expects adjusted EBITDA to be more than \$105 million.

---

## Recent News

### Updates Design of Phase III Studies on IW-3718 – Jul 21

Ironwood announced that it has updated the design of the two identical phase III studies evaluating IW-3718 following discussion with the FDA. The company stated that primary endpoint has been changed from the previous responder endpoint to a continuous endpoint for both studies — IW-3718-301 and IW-3718-302.

Moreover, the company will conduct an early assessment of IW-3718-302 study and plans to stop enrollment in the study. It anticipates to report data from a blinded early assessment of efficacy in this study in the fourth quarter of 2020.

### Discontinues MD-7246 Development – May 27

Ironwood announced that the delayed-release formulation of Linzess — MD-7246 — has failed to meet primary as well secondary endpoints in a phase II study. The study was evaluating MD-7246 in patients with abdominal pain associated with IBS-D. Data showed that MD-7246 failed to achieve statistically significant improvements in abdominal pain compared to placebo.

Based on the study data, Ironwood and its partner AbbVie are planning to discontinue the development of MD-7246.

Ironwood had previously reported data from another phase II study evaluating the candidate in patients with IBS-C in 2016. Data from the IBS-C study showed that MD-7246 numerically improved abdominal pain relative to placebo with no effect on bowel function.

### Provides Update on Impact of COVID-19 – Mar 26

Ironwood announced that it is continuing development of its pipeline candidates amid the coronavirus pandemic. The company has completed enrolment in the phase II study evaluating MD-7246 for the treatment of abdominal pain associated with IBS with diarrhea and continues to expect to report top-line data in mid-2020.

However, the company stated that the pandemic is impacting enrolment in the phase III study evaluating Linzess for treating GERD. The study has reached 70% of its enrolment target but the company is currently assessing the situation and plans to provide an update on timing for top-line data after having some clarity. Top-line data was previously expected in the second half of 2020.

### Settles Linzess Patent Litigation With Sandoz – Jan 6

Ironwood and partner Allergan announced that they have settled a patent litigation related to Linzess with Sandoz, the generic division of Novartis. Sandoz had filed an abbreviated new drug application, seeking approval for a generic version of Linzess in the United States. Per the settlement terms, Sandoz will be able to market generic version of Linzess, beginning Feb 5, 2030, subject to FDA approval.

### Amends Collaboration Agreement with AstraZeneca – Sep 18

Ironwood announced that it has amended the collaboration agreement with AstraZeneca related to development and commercialization of Linzess in China, including Hong Kong and Macau. Per the amended terms, Ironwood has granted AstraZeneca exclusive rights to develop, manufacture, and commercialize Linzess in these territories. AstraZeneca will be responsible for all expenses associated with Linzess and Ironwood will no longer be jointly funding the development and commercialization of Linzess neither will it share profits on the drug's sales in China. The company will receive royalties on net sales of Linzess in China and included territories.

Per the terms of the amended agreement, Ironwood is eligible to receive payments up to a total of \$125 million, which includes \$35 million in non-contingent payments and \$90 million payment contingent to achieving certain annual net sales targets. It received \$32.4 million of the non-contingent payments and recorded the same as revenues in the third quarter.

## Valuation

Ironwood's shares are down 23.4% in the year-to-date period and up 12.2% over the trailing 12-month period. Stocks in the Zacks sub-industry and sector are down 5.1% and up 1%, respectively, in the year-to-date period. Over the past year, stocks in the sub-industry are down 1.3% while stocks in the sector are up 9.1%.

The S&P 500 Index is up 3.8% in the year-to-date period and 16.4% in the past year.

The stock is currently trading at 3.82X trailing 12-month sales per share which compares to 2.2X for the Zacks sub-industry, 3.1X for the Zacks sector and 3.75X for the S&P 500 Index.

Over the past five years, the stock has traded as high as 15.07X and as low as 2.97X, with a 5-year median of 8.18X. Our Neutral recommendation indicates that the stock will perform in line with the market. Our \$11.00 price target reflects 4.12X trailing 12-month sales per share.

## Industry Analysis Zacks Industry Rank: Top 48% (122 out of 252)



## Top Peers

Company (Ticker)	Rec	Rank
Horizon Therapeutics Public Limited Company (HZNP)	Outperform	1
AbbVie Inc. (ABBV)	Neutral	3
Ardelyx, Inc. (ARDX)	Neutral	3
Bausch Health Cos Inc. (BHC)	Neutral	3
Evoke Pharma, Inc. (EVOK)	Neutral	4
Mallinckrodt public limited company (MNK)	Neutral	3
Teva Pharmaceutical Industries Ltd. (TEVA)	Neutral	3

Industry Comparison Industry: Medical - Drugs				Industry Peers		
	IRWD	X Industry	S&P 500	ABBV	HZNP	TEVA
Zacks Recommendation (Long Term)	Neutral	-	-	Neutral	Outperform	Neutral
Zacks Rank (Short Term)	3	-	-	3	1	3
VGM Score	C	-	-	A	D	C
Market Cap	1.63 B	147.93 M	23.30 B	163.99 B	15.70 B	13.02 B
# of Analysts	4	3	14	6	6	10
Dividend Yield	0.00%	0.00%	1.76%	5.08%	0.00%	0.00%
Value Score	C	-	-	A	D	A
Cash/Price	0.16	0.25	0.07	0.29	0.06	0.14
EV/EBITDA	18.20	-2.78	13.32	17.14	49.92	78.40
PEG Ratio	NA	1.14	2.94	1.49	1.93	0.81
Price/Book (P/B)	NA	3.54	3.19	11.13	6.61	0.88
Price/Cash Flow (P/CF)	17.64	11.93	12.51	8.99	21.92	3.06
P/E (F1)	24.62	17.90	22.02	8.88	35.21	4.77
Price/Sales (P/S)	3.81	7.18	2.53	4.53	10.35	0.77
Earnings Yield	4.12%	-14.56%	4.37%	11.26%	2.84%	20.97%
Debt/Equity	-6.25	0.01	0.77	5.57	0.62	1.66
Cash Flow (\$/share)	0.58	-0.50	6.94	10.33	3.47	3.89
Growth Score	B	-	-	C	D	F
Hist. EPS Growth (3-5 yrs)	NA%	5.38%	10.46%	21.34%	8.06%	-19.38%
Proj. EPS Growth (F1/F0)	-23.64%	15.66%	-6.80%	16.98%	11.34%	-7.75%
Curr. Cash Flow Growth	-168.58%	2.74%	5.39%	8.78%	10.70%	-9.67%
Hist. Cash Flow Growth (3-5 yrs)	20.48%	6.17%	8.55%	19.92%	39.60%	-6.21%
Current Ratio	12.10	3.68	1.33	0.86	2.39	1.09
Debt/Capital	NA%	5.17%	44.50%	84.78%	38.30%	62.41%
Net Margin	22.74%	-138.40%	10.13%	19.20%	34.09%	0.03%
Return on Equity	-134.49%	-62.90%	14.39%	-628.57%	20.63%	17.88%
Sales/Assets	1.12	0.27	0.51	0.37	0.37	0.30
Proj. Sales Growth (F1/F0)	-15.45%	0.00%	-1.51%	36.69%	28.41%	-3.57%
Momentum Score	F	-	-	B	B	C
Daily Price Chg	1.09%	0.00%	0.90%	0.38%	5.32%	-1.89%
1 Week Price Chg	-3.58%	-1.52%	0.14%	-2.27%	4.65%	0.44%
4 Week Price Chg	3.45%	0.58%	8.95%	-5.13%	31.14%	2.67%
12 Week Price Chg	-5.56%	7.38%	18.90%	3.31%	69.78%	8.66%
52 Week Price Chg	6.47%	-3.23%	1.18%	41.97%	175.68%	63.51%
20 Day Average Volume	2,226,184	286,725	2,057,775	6,629,981	2,310,520	8,581,259
(F1) EPS Est 1 week change	0.00%	0.00%	0.00%	0.06%	3.82%	-0.18%
(F1) EPS Est 4 week change	-3.71%	0.00%	1.36%	-0.11%	15.17%	0.34%
(F1) EPS Est 12 week change	-9.55%	0.31%	1.57%	2.48%	18.05%	2.98%
(Q1) EPS Est Mthly Chg	-17.95%	0.00%	0.54%	1.73%	22.51%	-1.42%

---

## Zacks Stock Rating System

We offer two rating systems that take into account investors' holding horizons: Zacks Rank and Zacks Recommendation. Each provides valuable insights into the future profitability of the stock and can be used separately or in combination with each other depending on your investment style.

### Zacks Recommendation

The Zacks Recommendation aims to predict performance over the next 6 to 12 months. The foundation for the quantitatively determined Zacks Recommendation is trends in the company's estimate revisions and earnings outlook. The Zacks Recommendation is broken down into 3 Levels; Outperform, Neutral and Underperform. Unlike many Wall Street firms, we have an excellent balance between the number of Outperform and Neutral recommendations. Our team of 70 analysts are fully versed in the benefits of earnings estimate revisions and how that is harnessed through the Zacks quantitative rating system. But we have given our analysts the ability to override the Zacks Recommendation for the 1200 stocks that they follow. The reason for the analyst over-rides is that there are often factors such as valuation, industry conditions and management effectiveness that a trained investment professional can spot better than a quantitative model.

### Zacks Rank

The Zacks Rank is our short-term rating system that is most effective over the one- to three-month holding horizon. The underlying driver for the quantitatively-determined Zacks Rank is the same as the Zacks Recommendation, and reflects trends in earnings estimate revisions.

---

### Zacks Style Scores

The Zacks Style Score is as a complementary indicator to the Zacks rating system, giving investors a way to focus on the highest rated stocks that best fit their own stock picking preferences.

Academic research has proven that stocks with the best Value, Growth and Momentum characteristics outperform the market. The Zacks Style Scores rate stocks on each of these individual styles and assigns a rating of A, B, C, D and F. We also produce the VGM Score (V for Value, G for Growth and M for Momentum), which combines the weighted average of the individual Style Scores into one score. This is perfectly suited for those who want their stocks to have the best scores across the board.

Value Score	C
Growth Score	B
Momentum Score	F
VGM Score	C

As an investor, you want to buy stocks with the highest probability of success. That means buying stocks with a Zacks Recommendation of Outperform, which also has a Style Score of an A or a B.

---

### Disclosures

**This report contains independent commentary to be used for informational purposes only. The analysts contributing to this report do not hold any shares of this stock. The analysts contributing to this report do not serve on the board of the company that issued this stock. The EPS and revenue forecasts are the Zacks Consensus estimates, unless indicated otherwise on the reports first page.** Additionally, the analysts contributing to this report certify that the views expressed herein accurately reflect the analysts personal views as to the subject securities and issuers. ZIR certifies that no part of the analysts compensation was, is, or will be, directly or indirectly, related to the specific recommendation or views expressed by the analyst in the report.

Additional information on the securities mentioned in this report is available upon request. This report is based on data obtained from sources we believe to be reliable, but is not guaranteed as to accuracy and does not purport to be complete. Any opinions expressed herein are subject to change.

ZIR is not an investment advisor and the report should not be construed as advice designed to meet the particular investment needs of any investor. Prior to making any investment decision, you are advised to consult with your broker, investment advisor, or other appropriate tax or financial professional to determine the suitability of any investment. This report and others like it are published regularly and not in response to episodic market activity or events affecting the securities industry.

This report is not to be construed as an offer or the solicitation of an offer to buy or sell the securities herein mentioned. ZIR or its officers, employees or customers may have a position long or short in the securities mentioned and buy or sell the securities from time to time. ZIR is not a broker-dealer. ZIR may enter into arms-length agreements with broker-dealers to provide this research to their clients. Zacks and its staff are not involved in investment banking activities for the stock issuer covered in this report.

ZIR uses the following rating system for the securities it covers. **Outperform-** ZIR expects that the subject company will outperform the broader U.S. equities markets over the next six to twelve months. **Neutral-** ZIR expects that the company will perform in line with the broader U.S. equities markets over the next six to twelve months. **Underperform-** ZIR expects the company will underperform the broader U.S. equities markets over the next six to twelve months.

No part of this report can be reprinted, republished or transmitted electronically without the prior written authorization of ZIR.